Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02230176 |
Title | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) |
Acronym | OCCLURANDOM |
Recruitment | Unknown status |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Gustave Roussy, Cancer Campus, Grand Paris |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | FRA |